



## Acceleron Pharma to Present at Two Upcoming Investor Conferences

**CAMBRIDGE, Mass.** – November 28, 2011 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it will give corporate presentations at two upcoming investor conferences. John Knopf, Ph.D., Chief Executive Officer, will provide a corporate presentation at the Piper Jaffray 23<sup>rd</sup> Annual Health Care Conference and Steven Ertel, Senior Vice President, Corporate Development, will present at the Oppenheimer 22<sup>nd</sup> Annual Healthcare Conference. The details for each presentation are shown below.

*Piper Jaffray 23<sup>rd</sup> Annual Health Care Conference*

Date: Wednesday, November 30, 2011  
Location: The New York Palace, New York City  
Time: 9:30 to 9:50 AM (EST)

*Oppenheimer 22<sup>nd</sup> Annual Healthcare Conference*

Date: Tuesday, December 13, 2011  
Location: The Waldorf=Astoria, New York City  
Time: 9:40 to 9:55 AM (EST)

### About Acceleron

Acceleron is a privately-held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel protein therapeutics for orphan diseases and cancer. Acceleron's scientific approach takes advantage of its unique insight to discover first-in-class therapies based on the TGF- $\beta$  protein superfamily. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company's internal GMP manufacturing capability to advance its therapeutic programs rapidly and efficiently. The investors in Acceleron include Advanced Technology Ventures, Alkermes, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For further information on Acceleron, please visit [www.acceleronpharma.com](http://www.acceleronpharma.com).

### CONTACT:

Acceleron Pharma:  
Steven Ertel, 617-649-9234  
Senior Vice President, Corporate Development

Maureen L. Suda (Media)  
Suda Communications LLC, 585-387-9248

###